B
Boston Oncology
Generics, Emerging Markets, Biosimilars | Boston Oncology
About Boston Oncology
Boston Oncology operates as a biogenerics company with a focus on licensing, local development, manufacturing, and distribution of pharmaceuticals across various therapeutic areas. The company was founded in 2012 by Dr. Abdullah Baaj with the mission to provide cost-effective, locally-produced therapeutics for cancers and inflammatory diseases in emerging nations. While it has headquarters in Cambridge, Massachusetts, its operational nerve center is in Riyadh, Saudi Arabia.
The company's business model centers on acquiring intellectual property and transferring technology to localize the manufacturing of generic chemotherapy and biologic pharmaceuticals in developing nations and emerging markets. This is exemplified by its GCC entity, Boston Oncology Arabia, which serves as a key part of its strategy and is aligned with Saudi Arabia's Vision 2030 by enhancing local healthcare services and manufacturing capabilities. A significant milestone was achieved in July 2024 when Boston Oncology Arabia secured a $35 million investment from TVM Capital Healthcare to advance its manufacturing facility in Sudair Industrial City. The company generates revenue through the commercialization of its licensed and locally produced medicines.
Initially concentrating on oncology, the company has since broadened its portfolio to include critical care, specialty generics, anti-infectives, and biosimilars. A key achievement has been the rapid expansion of its product portfolio approved by the Saudi Food and Drug Authority (SFDA), growing from zero in 2018 to a projected 61 by 2022, with a target of over 175 products. Its manufacturing facility in Saudi Arabia is GMP-certified and has an annual capacity of over 30 million vials. Boston Oncology serves government hospitals and is a preferred supplier to institutions like the King Faisal Specialist Hospital. In January 2025, a partnership was announced with SPIMACO to localize the production of oral oncology treatments in Saudi Arabia, further strengthening the region's pharmaceutical infrastructure.
Source: Dealroom company dataNews
Open roles
Boston Oncology in the Cambridge ecosystem
The Boston Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
TVM Capital Healthcare
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Boston Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Boston Oncology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
